Key clinical point: The development of exocrine pancreatic insufficiency (EPI) varied with the type of restrictive or malabsorptive bariatric surgery, i.e., sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD/DS).

Major finding: Six-hour ¹³C-cumulative recovery rate was significantly reduced (all P less than .001) in patients who underwent BPD/DS (25.6±13.5%) vs those who underwent RYGB (44.0±9.6%) or SG (47.6±9.3%) and the control group of patients who did not undergo bariatric surgery (45.0±6.1%). EPI was present in 78.8% of patients after BPD/DS, 8.3% of patients after RYGB, and 4.3% of patients after SG (P < .01).

Study details: This was a prospective study that assessed pancreatic function using a ¹³C-mixed triglyceride breath test in 95 adult patients who underwent bariatric surgery (RYGB, n=36; BPD/DS, n=36; SG, n=23) and 10 patients with obesity who formed the control group.

Disclosures: No source of funding was identified. JE Dominguez-Munoz received personal fees from Abbott Pharmaceuticals, AbbVie, and Viatris. Other authors declared no conflict of interests.

Source: Uribarri-Gonzalez L et al. Surg Obes Relat Dis. 2021 Jul 6. doi: 10.1016/j.soard.2021.06.019.

Key clinical point: The development of exocrine pancreatic insufficiency (EPI) varied with the type of restrictive or malabsorptive bariatric surgery, i.e., sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD/DS).

Major finding: Six-hour ¹³C-cumulative recovery rate was significantly reduced (all P less than .001) in patients who underwent BPD/DS (25.6±13.5%) vs those who underwent RYGB (44.0±9.6%) or SG (47.6±9.3%) and the control group of patients who did not undergo bariatric surgery (45.0±6.1%). EPI was present in 78.8% of patients after BPD/DS, 8.3% of patients after RYGB, and 4.3% of patients after SG (P < .01).

Study details: This was a prospective study that assessed pancreatic function using a ¹³C-mixed triglyceride breath test in 95 adult patients who underwent bariatric surgery (RYGB, n=36; BPD/DS, n=36; SG, n=23) and 10 patients with obesity who formed the control group.

Disclosures: No source of funding was identified. JE Dominguez-Munoz received personal fees from Abbott Pharmaceuticals, AbbVie, and Viatris. Other authors declared no conflict of interests.

Source: Uribarri-Gonzalez L et al. Surg Obes Relat Dis. 2021 Jul 6. doi: 10.1016/j.soard.2021.06.019.

Key clinical point: The development of exocrine pancreatic insufficiency (EPI) varied with the type of restrictive or malabsorptive bariatric surgery, i.e., sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD/DS).

Major finding: Six-hour ¹³C-cumulative recovery rate was significantly reduced (all P less than .001) in patients who underwent BPD/DS (25.6±13.5%) vs those who underwent RYGB (44.0±9.6%) or SG (47.6±9.3%) and the control group of patients who did not undergo bariatric surgery (45.0±6.1%). EPI was present in 78.8% of patients after BPD/DS, 8.3% of patients after RYGB, and 4.3% of patients after SG (P < .01).

Study details: This was a prospective study that assessed pancreatic function using a ¹³C-mixed triglyceride breath test in 95 adult patients who underwent bariatric surgery (RYGB, n=36; BPD/DS, n=36; SG, n=23) and 10 patients with obesity who formed the control group.

Disclosures: No source of funding was identified. JE Dominguez-Munoz received personal fees from Abbott Pharmaceuticals, AbbVie, and Viatris. Other authors declared no conflict of interests.

Source: Uribarri-Gonzalez L et al. Surg Obes Relat Dis. 2021 Jul 6. doi: 10.1016/j.soard.2021.06.019.

Key clinical point: Among Black women, ambient concentrations of ozone (O₃), but not particulate matter <2.5 microns (PM_2.5) or nitrogen dioxide (NO₂), were associated with an increased risk for uterine fibroids.

Major finding: Ambient O₃ concentrations were significantly associated with an increased risk for uterine fibroids (hazard ratio for a 1-interquartile range increase, 1.19; 95% confidence interval, 1.07-1.32), particularly in women aged <35 years and parous women. However, concentrations of PM_2.5 and NO₂ had no significant associations with uterine fibroids risk.

Study details: The data come from a prospective cohort study of 21,998 premenopausal Black women in the US.

Disclosures: This study was funded by the National Cancer Institute and the National Institute of Environmental Health Sciences. LA Wise reported relationships with AbbVie, Inc., Swiss Precision Diagnostics, Sandstone Diagnostics, FertilityFriend.com, and Kindara.com. M Jerrett reported receiving consultancy fees from the Health Effects Institute. The remaining authors declared no conflict of interests.

Source: Wesselink AK et al. Hum Reprod. 2021 May 13. doi: 10.1093/humrep/deab095.

Key clinical point: Among Black women, ambient concentrations of ozone (O₃), but not particulate matter <2.5 microns (PM_2.5) or nitrogen dioxide (NO₂), were associated with an increased risk for uterine fibroids.

Major finding: Ambient O₃ concentrations were significantly associated with an increased risk for uterine fibroids (hazard ratio for a 1-interquartile range increase, 1.19; 95% confidence interval, 1.07-1.32), particularly in women aged <35 years and parous women. However, concentrations of PM_2.5 and NO₂ had no significant associations with uterine fibroids risk.

Study details: The data come from a prospective cohort study of 21,998 premenopausal Black women in the US.

Disclosures: This study was funded by the National Cancer Institute and the National Institute of Environmental Health Sciences. LA Wise reported relationships with AbbVie, Inc., Swiss Precision Diagnostics, Sandstone Diagnostics, FertilityFriend.com, and Kindara.com. M Jerrett reported receiving consultancy fees from the Health Effects Institute. The remaining authors declared no conflict of interests.

Source: Wesselink AK et al. Hum Reprod. 2021 May 13. doi: 10.1093/humrep/deab095.

Key clinical point: Among Black women, ambient concentrations of ozone (O₃), but not particulate matter <2.5 microns (PM_2.5) or nitrogen dioxide (NO₂), were associated with an increased risk for uterine fibroids.

Major finding: Ambient O₃ concentrations were significantly associated with an increased risk for uterine fibroids (hazard ratio for a 1-interquartile range increase, 1.19; 95% confidence interval, 1.07-1.32), particularly in women aged <35 years and parous women. However, concentrations of PM_2.5 and NO₂ had no significant associations with uterine fibroids risk.

Study details: The data come from a prospective cohort study of 21,998 premenopausal Black women in the US.

Disclosures: This study was funded by the National Cancer Institute and the National Institute of Environmental Health Sciences. LA Wise reported relationships with AbbVie, Inc., Swiss Precision Diagnostics, Sandstone Diagnostics, FertilityFriend.com, and Kindara.com. M Jerrett reported receiving consultancy fees from the Health Effects Institute. The remaining authors declared no conflict of interests.

Source: Wesselink AK et al. Hum Reprod. 2021 May 13. doi: 10.1093/humrep/deab095.

Key clinical point: Single-port access (SPA) myomectomy in combination with uterine artery ligation (UAL) enables removal of large uterine fibroids while reducing blood loss.

Major finding: The median weight of total resected uterine fibroids was higher for the patients who received UAL vs those who did not (210 g vs 119 g; P = .023). There were no significant differences between the groups in terms of total surgery time, estimated blood loss, perioperative hemoglobin changes, postoperative analgesic use, and postoperative complications.

Study details: Surgical outcomes of 24 patients who underwent SPA myomectomy with UAL and 32 patients who underwent SPA myomectomy only were retrospectively reviewed.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Noh JJ et al. Taiwan J Obstet Gynecol. 2021 Jul 8. doi: 10.1016/j.tjog.2021.05.029.

Key clinical point: Single-port access (SPA) myomectomy in combination with uterine artery ligation (UAL) enables removal of large uterine fibroids while reducing blood loss.

Major finding: The median weight of total resected uterine fibroids was higher for the patients who received UAL vs those who did not (210 g vs 119 g; P = .023). There were no significant differences between the groups in terms of total surgery time, estimated blood loss, perioperative hemoglobin changes, postoperative analgesic use, and postoperative complications.

Study details: Surgical outcomes of 24 patients who underwent SPA myomectomy with UAL and 32 patients who underwent SPA myomectomy only were retrospectively reviewed.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Noh JJ et al. Taiwan J Obstet Gynecol. 2021 Jul 8. doi: 10.1016/j.tjog.2021.05.029.

Key clinical point: Single-port access (SPA) myomectomy in combination with uterine artery ligation (UAL) enables removal of large uterine fibroids while reducing blood loss.

Major finding: The median weight of total resected uterine fibroids was higher for the patients who received UAL vs those who did not (210 g vs 119 g; P = .023). There were no significant differences between the groups in terms of total surgery time, estimated blood loss, perioperative hemoglobin changes, postoperative analgesic use, and postoperative complications.

Study details: Surgical outcomes of 24 patients who underwent SPA myomectomy with UAL and 32 patients who underwent SPA myomectomy only were retrospectively reviewed.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Noh JJ et al. Taiwan J Obstet Gynecol. 2021 Jul 8. doi: 10.1016/j.tjog.2021.05.029.

Key clinical point: A prognostic index (PI) model was effective in predicting the recurrence of uterine fibroids following myomectomy.

Major finding: The high- and intermediate-risk groups had a 4.55- and 2.81-fold greater recurrence risk, respectively, for uterine fibroids than the low-risk group.

Study details: A retrospective multicenter study of 725 women who underwent myomectomy was used to develop the PI model. The PI formula was 1.5 (if 3-5 fibroids) or 2 (if >5 fibroids)+1 (if residue)+1 (if not submucosal)+1 (if combined endometriosis). Patients were characterized into low, intermediate, and high risks by PI cut-off values 1.25 and 3.75.

Disclosures: The study was supported by a grant from the Applied Basic Research Programs of Science and Technology Department of Sichuan Province. The authors declared no conflict of interests.

Source: Ming X et al. PLoS One. 2021 Jul 1. doi: 10.1371/journal.pone.0254142.

Key clinical point: A prognostic index (PI) model was effective in predicting the recurrence of uterine fibroids following myomectomy.

Major finding: The high- and intermediate-risk groups had a 4.55- and 2.81-fold greater recurrence risk, respectively, for uterine fibroids than the low-risk group.

Study details: A retrospective multicenter study of 725 women who underwent myomectomy was used to develop the PI model. The PI formula was 1.5 (if 3-5 fibroids) or 2 (if >5 fibroids)+1 (if residue)+1 (if not submucosal)+1 (if combined endometriosis). Patients were characterized into low, intermediate, and high risks by PI cut-off values 1.25 and 3.75.

Disclosures: The study was supported by a grant from the Applied Basic Research Programs of Science and Technology Department of Sichuan Province. The authors declared no conflict of interests.

Source: Ming X et al. PLoS One. 2021 Jul 1. doi: 10.1371/journal.pone.0254142.

Key clinical point: A prognostic index (PI) model was effective in predicting the recurrence of uterine fibroids following myomectomy.

Major finding: The high- and intermediate-risk groups had a 4.55- and 2.81-fold greater recurrence risk, respectively, for uterine fibroids than the low-risk group.

Study details: A retrospective multicenter study of 725 women who underwent myomectomy was used to develop the PI model. The PI formula was 1.5 (if 3-5 fibroids) or 2 (if >5 fibroids)+1 (if residue)+1 (if not submucosal)+1 (if combined endometriosis). Patients were characterized into low, intermediate, and high risks by PI cut-off values 1.25 and 3.75.

Disclosures: The study was supported by a grant from the Applied Basic Research Programs of Science and Technology Department of Sichuan Province. The authors declared no conflict of interests.

Source: Ming X et al. PLoS One. 2021 Jul 1. doi: 10.1371/journal.pone.0254142.

Key clinical point: High-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids demonstrated superior outcomes in terms of symptomatic relief, improvement in quality of life (QoL), recovery, and complications compared with surgery.

Major finding: Compared with the surgery group, the HIFU group demonstrated a greater reduction in uterine fibroid severity score at 6- and 12-month follow-up (P less than .05), greater increase in QoL score at 6- and 12-month follow-up (P < .05), and shorter duration of hospital stay and return to work (P less than .05). Differences in adverse events, symptom recurrence, reintervention, and pregnancy between the groups were not significant (P greater than .05).

Study details: The data come from a meta-analysis of 10 studies involving 4,450 women.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Liu L et al. Eur Radiol. 2021 Aug 1. doi: 10.1007/s00330-021-08156-6.

Key clinical point: High-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids demonstrated superior outcomes in terms of symptomatic relief, improvement in quality of life (QoL), recovery, and complications compared with surgery.

Major finding: Compared with the surgery group, the HIFU group demonstrated a greater reduction in uterine fibroid severity score at 6- and 12-month follow-up (P less than .05), greater increase in QoL score at 6- and 12-month follow-up (P < .05), and shorter duration of hospital stay and return to work (P less than .05). Differences in adverse events, symptom recurrence, reintervention, and pregnancy between the groups were not significant (P greater than .05).

Study details: The data come from a meta-analysis of 10 studies involving 4,450 women.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Liu L et al. Eur Radiol. 2021 Aug 1. doi: 10.1007/s00330-021-08156-6.

Key clinical point: High-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids demonstrated superior outcomes in terms of symptomatic relief, improvement in quality of life (QoL), recovery, and complications compared with surgery.

Major finding: Compared with the surgery group, the HIFU group demonstrated a greater reduction in uterine fibroid severity score at 6- and 12-month follow-up (P less than .05), greater increase in QoL score at 6- and 12-month follow-up (P < .05), and shorter duration of hospital stay and return to work (P less than .05). Differences in adverse events, symptom recurrence, reintervention, and pregnancy between the groups were not significant (P greater than .05).

Study details: The data come from a meta-analysis of 10 studies involving 4,450 women.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Liu L et al. Eur Radiol. 2021 Aug 1. doi: 10.1007/s00330-021-08156-6.

Key clinical point: Three-dimensional (3D) laparoscopic myomectomy for uterine fibroids has no additional surgical benefit compared with conventional two-dimensional (2D) laparoscopic myomectomy.

Major finding: There were no significant differences between the 3D and 2D groups in terms of operative blood loss (P = .421), change in serum hemoglobin levels (P = .553), and operative time (P = .344).

Study details: In a randomized controlled trial, 64 patients with symptomatic uterine fibroids were assigned either to 3D (n=32) or 2D (n=32) laparoscopic myomectomy.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Song T and Kang DY. Eur J Obstet Gynecol Reprod Biol. 2021 Jul 23. doi: 10.1016/j.ejogrb.2021.07.036.

Key clinical point: Three-dimensional (3D) laparoscopic myomectomy for uterine fibroids has no additional surgical benefit compared with conventional two-dimensional (2D) laparoscopic myomectomy.

Major finding: There were no significant differences between the 3D and 2D groups in terms of operative blood loss (P = .421), change in serum hemoglobin levels (P = .553), and operative time (P = .344).

Study details: In a randomized controlled trial, 64 patients with symptomatic uterine fibroids were assigned either to 3D (n=32) or 2D (n=32) laparoscopic myomectomy.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Song T and Kang DY. Eur J Obstet Gynecol Reprod Biol. 2021 Jul 23. doi: 10.1016/j.ejogrb.2021.07.036.

Key clinical point: Three-dimensional (3D) laparoscopic myomectomy for uterine fibroids has no additional surgical benefit compared with conventional two-dimensional (2D) laparoscopic myomectomy.

Major finding: There were no significant differences between the 3D and 2D groups in terms of operative blood loss (P = .421), change in serum hemoglobin levels (P = .553), and operative time (P = .344).

Study details: In a randomized controlled trial, 64 patients with symptomatic uterine fibroids were assigned either to 3D (n=32) or 2D (n=32) laparoscopic myomectomy.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Song T and Kang DY. Eur J Obstet Gynecol Reprod Biol. 2021 Jul 23. doi: 10.1016/j.ejogrb.2021.07.036.

Key clinical point: Women with uterine fibroids, especially those with pain symptoms or who have had a hysterectomy, may have an increased risk for certain mental health outcomes.

Major finding: After adjusting for confounders, women with uterine fibroids vs those without had higher rates of depression (hazard ratio [HR], 1.12; 95% confidence interval [CI], 1.10-1.13), anxiety (HR, 1.12; 95% CI, 1.10-1.13), and self-directed violence (HR, 1.46; 95% CI, 1.29-1.64). These associations were more pronounced in women experiencing pain symptoms and in those who underwent a hysterectomy.

Study details: The data come from a cohort study of 313,754 women aged 18-50 years with diagnosed uterine fibroids who were matched to 627,539 women without uterine fibroids.

Disclosures: The research was funded by AbbVie, and Aetion received funding for conducting the study. SE Chiuve, C Huisingh, and C Owens are employees of AbbVie receiving stock and/or stock options. N Petruski-Ivleva was an employee of Aetion when the study was being conducted and may hold stock options at Aetion. W Kuohung and LA Wise received consultancy fees from AbbVie, but did not receive payment for authorship.

Source: Chiuve SE et al. J Epidemiol Community Health. 2021 Jul 22. doi: 10.1136/jech-2020-214565.

Key clinical point: Women with uterine fibroids, especially those with pain symptoms or who have had a hysterectomy, may have an increased risk for certain mental health outcomes.

Major finding: After adjusting for confounders, women with uterine fibroids vs those without had higher rates of depression (hazard ratio [HR], 1.12; 95% confidence interval [CI], 1.10-1.13), anxiety (HR, 1.12; 95% CI, 1.10-1.13), and self-directed violence (HR, 1.46; 95% CI, 1.29-1.64). These associations were more pronounced in women experiencing pain symptoms and in those who underwent a hysterectomy.

Study details: The data come from a cohort study of 313,754 women aged 18-50 years with diagnosed uterine fibroids who were matched to 627,539 women without uterine fibroids.

Disclosures: The research was funded by AbbVie, and Aetion received funding for conducting the study. SE Chiuve, C Huisingh, and C Owens are employees of AbbVie receiving stock and/or stock options. N Petruski-Ivleva was an employee of Aetion when the study was being conducted and may hold stock options at Aetion. W Kuohung and LA Wise received consultancy fees from AbbVie, but did not receive payment for authorship.

Source: Chiuve SE et al. J Epidemiol Community Health. 2021 Jul 22. doi: 10.1136/jech-2020-214565.

Key clinical point: Women with uterine fibroids, especially those with pain symptoms or who have had a hysterectomy, may have an increased risk for certain mental health outcomes.

Major finding: After adjusting for confounders, women with uterine fibroids vs those without had higher rates of depression (hazard ratio [HR], 1.12; 95% confidence interval [CI], 1.10-1.13), anxiety (HR, 1.12; 95% CI, 1.10-1.13), and self-directed violence (HR, 1.46; 95% CI, 1.29-1.64). These associations were more pronounced in women experiencing pain symptoms and in those who underwent a hysterectomy.

Study details: The data come from a cohort study of 313,754 women aged 18-50 years with diagnosed uterine fibroids who were matched to 627,539 women without uterine fibroids.

Disclosures: The research was funded by AbbVie, and Aetion received funding for conducting the study. SE Chiuve, C Huisingh, and C Owens are employees of AbbVie receiving stock and/or stock options. N Petruski-Ivleva was an employee of Aetion when the study was being conducted and may hold stock options at Aetion. W Kuohung and LA Wise received consultancy fees from AbbVie, but did not receive payment for authorship.

Source: Chiuve SE et al. J Epidemiol Community Health. 2021 Jul 22. doi: 10.1136/jech-2020-214565.

Key clinical point: Increased expression levels of circulating microRNA (miRNA) like miR-140 and serum levels of few adipokines like leptin could serve as biomarkers for psoriatic arthritis (PsA) and could be particularly helpful in the differential diagnosis of peripheral PsA from other rheumatic diseases like rheumatoid arthritis (RA).

Major finding: MiR-140 and serum leptin levels were significantly higher in patients with PsA vs those with RA and healthy controls (HCs; both P < .001) and served as predictors of RA vs PsA (area under the receiver-operating characteristic curve, 0.91 and 0.83, respectively).

Study details: Findings are from a case-control study including 50 patients with peripheral PsA, 50 patients with RA, and 50 HCs.

Disclosures: No specific funding was received for this study. The authors declared no conflict of interests.

Source: Cheleschi S et al. Transl Res. 2021 Aug 8. doi: 10.1016/j.trsl.2021.08.001.

Key clinical point: Increased expression levels of circulating microRNA (miRNA) like miR-140 and serum levels of few adipokines like leptin could serve as biomarkers for psoriatic arthritis (PsA) and could be particularly helpful in the differential diagnosis of peripheral PsA from other rheumatic diseases like rheumatoid arthritis (RA).

Major finding: MiR-140 and serum leptin levels were significantly higher in patients with PsA vs those with RA and healthy controls (HCs; both P < .001) and served as predictors of RA vs PsA (area under the receiver-operating characteristic curve, 0.91 and 0.83, respectively).

Study details: Findings are from a case-control study including 50 patients with peripheral PsA, 50 patients with RA, and 50 HCs.

Disclosures: No specific funding was received for this study. The authors declared no conflict of interests.

Source: Cheleschi S et al. Transl Res. 2021 Aug 8. doi: 10.1016/j.trsl.2021.08.001.

Key clinical point: Increased expression levels of circulating microRNA (miRNA) like miR-140 and serum levels of few adipokines like leptin could serve as biomarkers for psoriatic arthritis (PsA) and could be particularly helpful in the differential diagnosis of peripheral PsA from other rheumatic diseases like rheumatoid arthritis (RA).

Major finding: MiR-140 and serum leptin levels were significantly higher in patients with PsA vs those with RA and healthy controls (HCs; both P < .001) and served as predictors of RA vs PsA (area under the receiver-operating characteristic curve, 0.91 and 0.83, respectively).

Study details: Findings are from a case-control study including 50 patients with peripheral PsA, 50 patients with RA, and 50 HCs.

Disclosures: No specific funding was received for this study. The authors declared no conflict of interests.

Source: Cheleschi S et al. Transl Res. 2021 Aug 8. doi: 10.1016/j.trsl.2021.08.001.

Key clinical point: A previous diagnosis of gout, uveitis, metabolic and lifestyle factors like obesity, alcohol consumption, and infections like pharyngitis and skin infections were potential risk factors for psoriatic arthritis (PsA), whereas statin use showed a negative association with PsA.

Major finding: A previous diagnosis of gout (odds ratio [OR], 2.19), uveitis (OR, 3.79), alcohol use (OR, 1.67), obesity (OR, 1.64), pharyngitis (OR, 1.23), and skin infection (OR, 1.37; all P < .001) were significant risk factors for PsA. The use of statin was negatively associated with PsA (OR, 0.53; P < .001).

Study details: This was a set of 4 separate case-control studies conducted in parallel and included cases of incident PsA (n=7,594), psoriasis (n=111,375), rheumatoid arthritis (RA; n=28,341), and ankylosing spondylitis (AS; n=3,253) matched to control participants (PsA, n=75,930; psoriasis, n=1113,345; RA, n=283,226; and AS, n=32,530).

Disclosures: This work was supported by grants from the National Institute of Health and internal grants from the University of Pennsylvania. Dr. Gelfand, Dr. Love, and Dr. Ogdie declared receiving research grants, honoraria, and reimbursement from and/or serving as a consultant for various sources.

Source: Meer E et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210006.

Key clinical point: A previous diagnosis of gout, uveitis, metabolic and lifestyle factors like obesity, alcohol consumption, and infections like pharyngitis and skin infections were potential risk factors for psoriatic arthritis (PsA), whereas statin use showed a negative association with PsA.

Major finding: A previous diagnosis of gout (odds ratio [OR], 2.19), uveitis (OR, 3.79), alcohol use (OR, 1.67), obesity (OR, 1.64), pharyngitis (OR, 1.23), and skin infection (OR, 1.37; all P < .001) were significant risk factors for PsA. The use of statin was negatively associated with PsA (OR, 0.53; P < .001).

Study details: This was a set of 4 separate case-control studies conducted in parallel and included cases of incident PsA (n=7,594), psoriasis (n=111,375), rheumatoid arthritis (RA; n=28,341), and ankylosing spondylitis (AS; n=3,253) matched to control participants (PsA, n=75,930; psoriasis, n=1113,345; RA, n=283,226; and AS, n=32,530).

Disclosures: This work was supported by grants from the National Institute of Health and internal grants from the University of Pennsylvania. Dr. Gelfand, Dr. Love, and Dr. Ogdie declared receiving research grants, honoraria, and reimbursement from and/or serving as a consultant for various sources.

Source: Meer E et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210006.

Key clinical point: A previous diagnosis of gout, uveitis, metabolic and lifestyle factors like obesity, alcohol consumption, and infections like pharyngitis and skin infections were potential risk factors for psoriatic arthritis (PsA), whereas statin use showed a negative association with PsA.

Major finding: A previous diagnosis of gout (odds ratio [OR], 2.19), uveitis (OR, 3.79), alcohol use (OR, 1.67), obesity (OR, 1.64), pharyngitis (OR, 1.23), and skin infection (OR, 1.37; all P < .001) were significant risk factors for PsA. The use of statin was negatively associated with PsA (OR, 0.53; P < .001).

Study details: This was a set of 4 separate case-control studies conducted in parallel and included cases of incident PsA (n=7,594), psoriasis (n=111,375), rheumatoid arthritis (RA; n=28,341), and ankylosing spondylitis (AS; n=3,253) matched to control participants (PsA, n=75,930; psoriasis, n=1113,345; RA, n=283,226; and AS, n=32,530).

Disclosures: This work was supported by grants from the National Institute of Health and internal grants from the University of Pennsylvania. Dr. Gelfand, Dr. Love, and Dr. Ogdie declared receiving research grants, honoraria, and reimbursement from and/or serving as a consultant for various sources.

Source: Meer E et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210006.

Key clinical point: Psoriatic arthritis (PsA) was not associated with a significant increase in risk for all-cause mortality in the more recent era between 2003 and 2018. Moreover, the major causes of death in PsA were not different than those commonly reported in the general population.

Major finding: The number of deaths was similar in PsA and control groups (8.9% and 7.9%, respectively), and the association between PsA and a higher risk for all-cause mortality was not significant (hazard ratio, 1.02; 95% confidence interval, 0.90-1.15). In the general population, malignancy (26.0%) and ischemic heart disease (15.8%) were the leading causes of death in patients with PsA.

Study details: Findings are from an analysis of a cohort of 5,275 adults newly diagnosed with PsA between 2003 and 2018, matched with 21,011 control participants and followed for 7.2±4.4 years.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Haddad A et al. J Rheumatol. 2021 Jul 15. doi: 10.3899/jrheum.210159. 

Key clinical point: Psoriatic arthritis (PsA) was not associated with a significant increase in risk for all-cause mortality in the more recent era between 2003 and 2018. Moreover, the major causes of death in PsA were not different than those commonly reported in the general population.

Major finding: The number of deaths was similar in PsA and control groups (8.9% and 7.9%, respectively), and the association between PsA and a higher risk for all-cause mortality was not significant (hazard ratio, 1.02; 95% confidence interval, 0.90-1.15). In the general population, malignancy (26.0%) and ischemic heart disease (15.8%) were the leading causes of death in patients with PsA.

Study details: Findings are from an analysis of a cohort of 5,275 adults newly diagnosed with PsA between 2003 and 2018, matched with 21,011 control participants and followed for 7.2±4.4 years.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Haddad A et al. J Rheumatol. 2021 Jul 15. doi: 10.3899/jrheum.210159. 

Key clinical point: Psoriatic arthritis (PsA) was not associated with a significant increase in risk for all-cause mortality in the more recent era between 2003 and 2018. Moreover, the major causes of death in PsA were not different than those commonly reported in the general population.

Major finding: The number of deaths was similar in PsA and control groups (8.9% and 7.9%, respectively), and the association between PsA and a higher risk for all-cause mortality was not significant (hazard ratio, 1.02; 95% confidence interval, 0.90-1.15). In the general population, malignancy (26.0%) and ischemic heart disease (15.8%) were the leading causes of death in patients with PsA.

Study details: Findings are from an analysis of a cohort of 5,275 adults newly diagnosed with PsA between 2003 and 2018, matched with 21,011 control participants and followed for 7.2±4.4 years.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Haddad A et al. J Rheumatol. 2021 Jul 15. doi: 10.3899/jrheum.210159.